RxDoctor Payments Data

Jose Tafur Soto, MD

Interventional Cardiology · New Orleans, LANPI 1730448960

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (29.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Medtronic at 51.5% of the total. 2025 is the largest year on record at $11,546, 8.5 times the $1,357 reported in 2019.

$43,690in general payments, 2019–2025

Across 281 payments — averaging $155.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$22K
  • Edwards Lifesciences$15K
  • Boston Scientific$857
  • Abiomed$835
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$742
  • Johnson & Johnson$712
  • plus $3K from 19 others
$375,033in research payments, 2019–2025

Across 57 payments — averaging $6579.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$354K
  • Abiomed$14K
  • Boston Scientific$8K

What the payments were for

  • Consulting fees$8,90020%
  • Speaking & faculty fees$13,04130%
  • Travel & lodging$10,59624%
  • Food & beverage$11,04525%
  • Entertainment$1090%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,690 in reported general payments places this provider in the 80th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$94,192
Medicare patients
384
Services billed
762

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab15$7,936
Fesoterodine Fumarate ErFesoterodine Fumarate13$965
Ranolazine ErRanolazine13$772
Atorvastatin Calcium31$512
Amlodipine-ValsartanAmlodipine Besylate/Valsartan13$495
ClopidogrelClopidogrel Bisulfate75$494
Rosuvastatin Calcium14$301
Sertraline Hcl13$273
Trazodone Hcl12$252
Metoprolol Succinate17$194
Isosorbide Mononitrate ErIsosorbide Mononitrate26$184
Metoprolol Tartrate15$169
Pravastatin Sodium20$166
Lisinopril21$166
Nitroglycerin18$155

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →